Kamal Ummed, MD
Hematology & Oncology · Atlanta, GANPI 1689725228
Payments from drug & device makers
Across 78 payments — averaging $31.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$265
- Exelixis Inc.$241
- Novartis$211
- Pfizer$177
- Springworks Therapeutics, Inc.$159
- Exeltis, USA Inc.$138
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,20891%
- Education$2199%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $265 |
| Exelixis Inc. | 2 | $241 |
| Novartis | 8 | $211 |
| Pfizer | 8 | $177 |
| Springworks Therapeutics, Inc. | 2 | $159 |
| Exeltis, USA Inc. | 1 | $138 |
| Bristol Myers Squibb | 5 | $130 |
| Amgen | 1 | $125 |
| Johnson & Johnson | 4 | $91 |
| Daiichi Sankyo Inc. | 3 | $75 |
| Sanofi | 2 | $65 |
| AbbVie | 2 | $56 |
| Incyte Corporation | 2 | $49 |
| Deciphera Pharmaceuticals Inc. | 2 | $47 |
| Eisai Inc. | 2 | $45 |
| Beigene USA, Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $42 |
| Tersera Therapeutics LLC | 1 | $35 |
| Merck | 1 | $32 |
| Beone Medicines USA, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Tempus AI, Inc | 1 | $30 |
| Astellas Pharma US Inc | 1 | $30 |
| Stemline Therapeutics Inc. | 1 | $28 |
| GSK | 1 | $26 |
| ADC Therapeutics America, Inc. | 1 | $26 |
| Syndax Pharmaceuticals, Inc. | 1 | $26 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| AMAG Pharmaceuticals, Inc. | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Dova Pharmaceuticals | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,427 in reported general payments places this provider in the 30th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 17 | $282,607 |
| Pazopanib Hcl | 22 | $217,950 |
| JakafiRuxolitinib Phosphate | 13 | $213,009 |
| NinlaroIxazomib Citrate | 12 | $158,798 |
| Imatinib Mesylate | 13 | $13,885 |
| XareltoRivaroxaban | 12 | $11,203 |
| EliquisApixaban | 13 | $7,521 |
| Dexamethasone | 20 | $322 |
| Gabapentin | 36 | $280 |
| Potassium Chloride | 29 | $235 |
| Letrozole | 14 | $229 |
| Prochlorperazine Maleate | 13 | $153 |
| Ondansetron Hcl | 13 | $128 |
| Pantoprazole Sodium | 19 | $69 |
| Lorazepam | 15 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $177 | $290,12930 claims |
| Incyte CorporationJakafi | $49 | $213,00913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $32 | $158,79812 claims |
| Johnson & JohnsonXarelto | $91 | $11,20312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Atlanta
- Mehmet BilenAtlanta$21.7M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
- Conor SteuerAtlanta$4.4M
- Anthony HunterAtlanta$4.3M
- Robert BrownAtlanta$4.2M
- Rodolfo BordoniAtlanta$4M
- Kristie BlumAtlanta$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.